

**STATEMENT OF CONSOLIDATED AUDITED RESULTS
FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2014**

(₹ in crores)

Particulars	Quarter Ended			Year Ended	
	31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
	Audited	Unaudited	Audited	Audited	Audited
1. Income from operations					
a) Net sales/Income from operations (Net of excise duty)	2429.28	2552.63	1916.99	9752.80	8086.82
b) Other operating income	90.24	28.15	61.65	347.59	192.51
Total income from operations (net)	2519.52	2580.78	1978.64	10100.39	8279.33
2. Expenses					
a) Cost of materials consumed	949.27	895.91	696.29	3376.22	2725.89
b) Purchases of stock-in-trade	61.88	244.06	70.90	562.86	517.32
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7.61)	(140.90)	(57.42)	(64.25)	(290.60)
d) Employee benefits expense	427.93	402.82	274.62	1542.96	1036.02
e) Depreciation and amortisation expense	105.01	91.17	85.09	372.64	330.48
f) Other expenses	678.77	711.62	568.47	2549.55	2092.85
Total expenses	2215.25	2204.68	1637.95	8339.98	6411.96
3. Profit (+)/Loss (-) from operations before other income, finance costs and exceptional item (1-2)	304.27	376.10	340.69	1760.41	1867.37
4. Other income	77.52	52.39	56.56	265.37	222.14
5. Profit (+)/Loss (-) before finance costs and exceptional item (3+4)	381.79	428.49	397.25	2025.78	2089.51
6. Finance costs	34.11	33.26	18.78	145.74	33.91
7. Profit (+)/Loss (-) before exceptional item and tax (5-6)	347.68	395.23	378.47	1880.04	2055.60
8. Exceptional item	-	-	-	-	39.77
9. Profit (+)/Loss (-) before tax (7+8)	347.68	395.23	378.47	1880.04	2095.37
10. Tax expense	75.30	98.70	102.72	463.38	544.31
11. Net Profit (+)/Loss (-) after tax (9-10)	272.38	296.53	275.75	1416.66	1551.06
12. Share of Profit (+) / Loss (-) of associates	(3.10)	(6.11)	0.74	(12.32)	(6.21)
13. Minority Interest	8.59	6.11	-	15.93	-
14. Net Profit (+) / Loss (-) after minority interest and share of profit/loss of associates (11+12-13)	260.69	284.31	276.49	1388.41	1544.85
15. Paid-up equity share capital (Face Value ₹ 2 per equity share)	160.58	160.58	160.58	160.58	160.58
16. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year					8849.13
17. Earnings per share (₹)					
- Basic	*3.25	*3.54	*3.44	17.29	19.24
- Diluted	*3.24	*3.54	*3.44	17.27	19.24

* Not Annualised

Particulars	Quarter Ended			Year Ended	
	31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
A. PARTICULARS OF SHAREHOLDING					
1. Public shareholding					
- Number of shares	498568383	498311105	500983877	498568383	500983877
- Percentage of shareholding	62.09	62.06	62.40	62.09	62.40
2. Promoters and Promoter Group Shareholding					
a) Pledged/Encumbered					
- Number of shares	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
b) Non-Encumbered					
- Number of shares	295485978	295485978	295485978	295485978	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the company)	36.80	36.80	36.80	36.80	36.80

Particulars	Quarter Ended 31.03.2014
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	15
Disposed of during the quarter	15
Remaining unresolved at the end of the quarter	NIL

Notes:

1. The Company is essentially in the pharmaceutical business segment.
2. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.
3. The Directors at their meeting held today recommended payment of dividend of ₹2 per equity share (face value ₹2 per equity share) for the year 2013-2014 amounting to ₹160.58 crores.
4. The consolidated accounts have been prepared in accordance with the principles set out in Accounting Standard 21 - Consolidated Financial Statements, Accounting Standard 23 - Accounting for Investments in Associates and Accounting Standard 27 - Financial Reporting in Joint Ventures in Consolidated Financial Statements notified in the Companies (Accounting Standard) Rules 2006. The financial results of associates and joint venture have been included in the consolidated results on the basis of management accounts not reviewed by the auditors.
5. In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts in Mumbai, Karnataka and Allahabad wherein it was held in favour of the Company. The orders of Hon'ble High Court of Allahabad and Bombay were challenged before the Hon'ble Supreme Court of India by the Government. Although in the challenge to the decision of the Hon'ble Bombay High Court, the Hon'ble Supreme Court of India restored the matter to the Hon'ble Bombay High Court in August 2003 for interpreting the Drug Policy on the basis of directions and principles laid down by them and the same was pending, in the challenge to the Hon'ble High Court of Allahabad's order, in February 2013, the Hon'ble Supreme Court of India transferred the Bombay High Court petition also before itself for a final hearing on both the matters. In an earlier order, the Hon'ble Supreme Court has already restrained the Government from taking any coercive action against the Company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand received by the company up to date aggregating to ₹1768.51 crores.

6. The Audited Standalone financial results for the quarter and year ended 31st March, 2014 is available on the Company's website i.e. www.cipla.com and on the Stock Exchange's website: www.bseindia.com and www.nseindia.com. The key standalone financial information are as under:

(₹ in crores)

Particulars	Quarter Ended			Year Ended	
	31.03.2014	31.12.2013	31.03.2013	31.03.2014	31.03.2013
	Audited	Unaudited	Audited	Audited	Audited
Total income from operations (net)	2194.19	2253.20	1900.29	9034.95	8015.37
Profit before tax	345.64	345.64	372.02	1818.34	2011.86
Profit after tax	276.64	260.77	267.56	1388.34	1507.11

7. During the quarter ended 31st March, 2014, in accordance with Employee Stock Option Scheme ("ESOS 2013 - A") dated 31st October, 2013, the Company has granted 85,194 stock options to employees at an exercise price equal to face value of the equity share. These options would vest not earlier than 1 year and not later than 2 years from the date of grant of options.
8. The figures of the previous year/period have been regrouped/recast to render them comparable with the figures of the current period.
9. The Audited Consolidated Statement of assets and liabilities is as under:

(₹ in crores)

Particulars	Year ended	
	31.03.2014	31.03.2013
A. EQUITY AND LIABILITIES		
1. Shareholders' fund		
(a) Share capital	160.58	160.58
(b) Reserves and surplus	9889.77	8858.10
Shareholders' fund	10050.35	9018.68
2. Minority Interest	49.58	-
3. Non-current liabilities		
(a) Long-term borrowings	317.87	0.55
(b) Deferred tax liabilities (net)	311.85	281.57
(c) Other long-term liabilities	32.57	30.00
(d) Long-term provisions	77.44	50.37
Non-current liabilities	739.73	362.49
4. Current liabilities		
(a) Short-term borrowings	910.47	966.38
(b) Trade payables	979.53	828.36
(c) Other current liabilities	408.67	250.89
(d) Short-term provisions	264.91	232.00
Current liabilities	2563.58	2277.63
Total	13403.24	11658.80
B. ASSETS		
1. Non-current assets		
(a) Fixed assets-Tangible	3995.94	3609.97
(b) Fixed assets-Intangible	7.44	-
(c) Capital Work-in-Progress- Tangible	353.64	367.44
(d) Intangible Assets under Development	88.20	10.35
(e) Goodwill on consolidation	2493.09	-
(f) Non-current investments	397.14	415.69
(g) Deferred Tax Assets (Net)	2.88	1.03
(h) Long-term loans and advances	301.49	357.80
(i) Other non-current assets	112.05	112.54
Non-current assets	7751.87	4874.82
2. Current assets		
(a) Current investments	311.43	2116.75
(b) Inventories	2895.26	2387.07
(c) Trade receivables	1638.89	1668.84
(d) Cash and cash equivalents	175.16	143.01
(e) Short-term loans and advances	595.49	466.03
(f) Other current assets	35.14	2.28
Current assets	5651.37	6783.98
Total	13403.24	11658.80

- 4 -

10. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 29th May 2014.

By order of the Board
For **CIPLA LIMITED**

Mumbai
29th May 2014

Subhanu Saxena
Managing Director and Global Chief Executive Officer